D-Dimer elevation and adverse outcomes.

Thumbnail Image
View / Download169.49 KB

Date

2015-01

Authors

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

493
views
485
downloads

Citation Stats

Abstract

D-Dimer is a biomarker of fibrin formation and degradation. While a D-dimer within normal limits is used to rule out the diagnosis of deep venous thrombosis and pulmonary embolism among patients with a low clinical probability of venous thromboembolism (VTE), the prognostic association of an elevated D-dimer with adverse outcomes has received far less emphasis. An elevated D-dimer is independently associated with an increased risk for incident VTE, recurrent VTE, and mortality. An elevated D-dimer is an independent correlate of increased mortality and subsequent VTE across a broad variety of disease states. Therefore, medically ill subjects in whom the D-dimer is elevated constitute a high risk subgroup in which the prospective evaluation of the efficacy and safety of antithrombotic therapy is warranted.

Type

Journal article

Department

Description

Provenance

Subjects

Biomarkers, Female, Fibrin Fibrinogen Degradation Products, Fibrinolytic Agents, Humans, Male, Venous Thromboembolism, Venous Thrombosis

Citation

Permalink

https://hdl.handle.net/10161/13934

Published Version (Please cite this version)

10.1007/s11239-014-1101-6

Publication Info

Halaby, Rim, Christopher J Popma, Ander Cohen, Gerald Chi, Marcelo Rodrigues Zacarkim, Gonzalo Romero, Samuel Z Goldhaber, Russell Hull, et al. (2015). D-Dimer elevation and adverse outcomes. J Thromb Thrombolysis, 39(1). pp. 55–59. 10.1007/s11239-014-1101-6 Retrieved from https://hdl.handle.net/10161/13934.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.

Collections

Scholarly Articles
Full item page

Scholars@Duke

Hernandez

Adrian Felipe Hernandez

Duke Health Cardiology Professor
Mentz

Robert John Mentz

Associate Professor of Medicine

I am a cardiologist with a clinical and research interest in heart failure (going from Failure to Function), including advanced therapies such as cardiac transplantation and mechanical assist devices or “heart pumps."

I serve our group as Chief of the Heart Failure Section.

I became a heart failure cardiologist in order to help patients manage their chronic disease over many months and years. I consider myself strongly committed to compassionate patient care with a focus on quality of life and patient preference.

I am the Editor in Chief of the Journal of Cardiac Failure - The official journal of the Heart Failure Society of America.

My research interests are focused on treating co-morbid diseases in heart failure patients and improving outcomes across the cardiovascular spectrum through clinical trials and outcomes research. Below, you will find my specific research interests:

  •     Cardiometabolic disease
  •     Co-morbidity characterization (diabetes, sleep apnea, renal failure) in heart failure
  •     Phenotypic characterization and risk prognostication of patients with heart failure
  •     Role of surrogate and nonfatal endpoints in clinical heart failure trials
  •     Biomarkers in heart failure
  •     Novel pharmacological and non-pharmacological approaches to heart failure
  •     Improving site-based heart failure research

Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.